Gender-specific antitumor action of aspirin in a murine model of a T-cell lymphoma bearing host

Blood Cells, Molecules, and Diseases

Volumn 48, Issue 2, 2012, Pages 137-144

  Kumar, Anjani ^a   Vishvakarma, Naveen Kumar ^a   Bharti, Alok Chandra ^b   Singh, Sukh Mahendra ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

Author keywords

Apoptosis; Aspirin; Dalton's lymphoma; Gender dimorphism; T cell lymphoma

Indexed keywords

ACETYLSALICYLIC ACID; CAD PROTEIN; ESTROGEN; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 10; LACTIC ACID; NITRITE; PROTEIN BCL 2; PROTEIN P53; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE; HIF 1ALPHA GENE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; T CELL LYMPHOMA; TUMOR MICROENVIRONMENT; TUMOR REGRESSION;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; ASPIRIN; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, T-CELL; MALE; MICE; MICE, INBRED BALB C; SEX FACTORS; TUMOR MICROENVIRONMENT;

MURINAE;

EID: 84856379168     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2011.10.006     Document Type: Article

References (51)

1. Sereno M., Brunello A., Chiappori A., Barriuso J., Casado E., Belda C., de Castro J., Feliu J., Gonzalez-Baron M. Cardiac toxicity: old and new issues in anti-cancer drugs. Clin. Transl. Oncol. 2008, 10:35-46.
2. Wittig A., Engenhart-Cabillic R. Cardiac side effects of conventional and particle radiotherapy in cancer patients. Herz. 2011, 36:311-324.
3. Ng A.K. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br. J. Haematol. 2011, 154:23-31.
4. Johnsen S.P., Larsson H., Tarone R.E., McLaughlin J.K., Norgard B., Friis S., Sorensen H.T. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch. Intern. Med. 2005, 165:978-984.
5. Bellosillo B., Pique M., Barragan M., Castano E., Villamor N., Colomer D., Montserrat E., Pons G., Gil J. Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 1998, 92:1406-1414.
6. Dikshit P., Chatterjee M., Goswami A., Mishra A., Jana N.R. Aspirin induces apoptosis through the inhibition of proteasome function. J. Biol. Chem. 2006, 281:29228-29235.
7. Elwood P.C., Gallagher A.M., Duthie G.G., Mur L.A., Morgan G. Aspirin, salicylates, and cancer. Lancet 2009, 373:1301-1309.
8. Dias M.C., Votto A.P., Filgueira D.D., Almeida D.V., Vallochi A.L., MG D.O., Marins L.F., Trindade G.S. Anti-MDR and antitumoral action of acetylsalicylic acid on leukemic cells. Biosci. Rep. 2011, 31:391-398.
9. Iglesias-Serret D., Pique M., Barragan M., Cosialls A.M., Santidrian A.F., Gonzalez-Girones D.M., Coll-Mulet L., de Frias M., Pons G., Gil J. Aspirin induces apoptosis in human leukemia cells independently of NF-kappaB and MAPKs through alteration of the Mcl-1/Noxa balance. Apoptosis 2010, 15:219-229.
10. Kopp E., Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994, 265:956-959.
11. Garber K. Aspirin for cancer chemoprevention: still a headache?. J. Natl. Cancer Inst. 2004, 96:252-253.
12. Kumar A., Vishvakarma N.K., Tyagi A., Bharti A.C., Singh S.M. Anti-neoplastic action of aspirin against a T cell lymphoma involves alteration in tumor microenvironment and regulation of tumor cell survival. Biosci. Rep. 2012, 32:91-104.
13. Gupta V., Singh S.M. Gender dimorphism of tumor growth: role of gonadal hormones in differential regulation of apoptosis of a murine T cell lymphoma. J. Biomed. Sci. 2008, 15:147-162.
14. Singh M.P., Rai A.K., Singh S.M. Gender dimorphism in the progressive in vivo growth of a T cell lymphoma: involvement of cytokines and gonadal hormones. J. Reprod. Immunol. 2005, 65:17-32.
15. Atwal G.S., Rabadan R., Lozano G., Strong L.C., Ruijs M.W., Schmidt M.K., van't Veer L.J., Nevanlinna H., Tommiska J., Aittomaki K., Bougeard G., Frebourg T., Levine A.J., Bond G.L. An information-theoretic analysis of genetics, gender and age in cancer patients. PLoS One 2008, 3:e1951.
16. Folkerd E.J., Dowsett M. Influence of sex hormones on cancer progression. J. Clin. Oncol. 2010, 28:4038-4044.
17. De Giorgi V., Gori A., Alfaioli B., Papi F., Grazzini M., Rossari S., Lotti T., Massi D. Influence of sex hormones on melanoma. J. Clin. Oncol. 2010, 29:e94-e95. author reply e96.
18. Gordon M.A., Zhang W., Yang D., Iqbal S., El-Khouiery A., Nagashima F., Lurje G., Labonte M., Wilson P., Sherrod A., Ladner R.D., Lenz H.J. Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. Pharmacogenomics 2010, 12:27-39.
19. Gupta V., Singh S.M. Sex dimorphism in antitumor response of chemotherapeutic drug cisplatin in a murine host-bearing a T-cell lymphoma. Anticancer Drugs 2008, 19:583-592.
20. Montgomery P.R., Berger L.G., Mitenko P.A., Sitar D.S. Salicylate metabolism: effects of age and sex in adults. Clin. Pharmacol. Ther. 1986, 39:571-576.
21. Baker J.A., Weiss J.R., Czuczman M.S., Menezes R.J., Ambrosone C.B., Moysich K.B. Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control 2005, 16:301-308.
22. Singh V., Singh M.P., Singh S.M. Cell density-dependent alterations in tumorigenic potential of a murine T-cell lymphoma: implication in the evolution of multidrug resistance in tumor cells. Anticancer Drugs 2008, 19:793-804.
23. Singh V., Singh S.M. Progressive tumor growth-associated altered tumor microenvironment: implications in a tumor stage-dependent modulation in survival of a murine T cell lymphoma. J. Cancer Res. Clin. Oncol. 2009, 135:1015-1024.
24. Singh V., Singh S.M. A tumour stage-dependent evolution of drug resistant T cell lymphoma: role of soluble mediators of tumour and host origin. Leuk. Res. 2009, 33:700-709.
25. Verma V.K., Singh V., Singh M.P., Singh S.M. Treadmill exercise-dependent tumor growth retardation in T-cell lymphoma-bearing host displays gender dimorphism. Oncol. Res. 2010, 18:293-304.
26. Vishvakarma N.K., Kumar A., Singh S.M. Role of curcumin-dependent modulation of tumor microenvironment of a murine T cell lymphoma in altered regulation of tumor cell survival. Toxicol. Appl. Pharmacol. 2011, 252:298-306.
27. Vishvakarma N.K., Singh S.M. Mechanisms of tumor growth retardation by modulation of pH regulation in the tumor-microenvironment of a murine T cell lymphoma. Biomed. Pharmacother. 2011, 65:27-39.
28. Vishvakarma N.K., Singh S.M. Augmentation of myelopoiesis in a murine host bearing a T cell lymphoma following in vivo administration of proton pump inhibitor pantoprazole. Biochimie 2011, 93:1786-1796.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
30. Kusumbe A.P., Bapat S.A. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res. 2009, 69:9245-9253.
31. Somoza B., Guzman R., Cano V., Merino B., Ramos P., Diez-Fernandez C., Fernandez-Alfonso M.S., Ruiz-Gayo M. Induction of cardiac uncoupling protein-2 expression and adenosine 5'-monophosphate-activated protein kinase phosphorylation during early states of diet-induced obesity in mice. Endocrinology 2007, 148:924-931.
32. Benedito M.A. Gender differences in the activities of aspirin-esterases in rat tissues. Braz. J. Med. Biol. Res. 1998, 31:1113-1118.
33. Bukhari N.I., Zafar A., Shamsi W.R., Bashir M.A., Mirza A.A. Bioequivalence assessment of two enteric-coated aspirin brands, Nu-Seals and Loprin, after a single oral dose of 150mg in healthy male adults. Therapie 2005, 60:167-173.
34. Chiang N., Hurwitz S., Ridker P.M., Serhan C.N. Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial. Arterioscler. Thromb. Vasc. Biol. 2006, 26:e14-e17.
35. Weir N.M., Selvendiran K., Kutala V.K., Tong L., Vishwanath S., Rajaram M., Tridandapani S., Anant S., Kuppusamy P. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol. Ther. 2007, 6:178-184.
36. Selvendiran K., Tong L., Vishwanath S., Bratasz A., Trigg N.J., Kutala V.K., Hideg K., Kuppusamy P. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J. Biol. Chem. 2007, 282:28609-28618.
37. Montopoli M., Ragazzi E., Froldi G., Caparrotta L. Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells. Cell Prolif. 2009, 42:195-206.
38. DuBois R.N. Aspirin and breast cancer prevention: the estrogen connection. JAMA 2004, 291:2488-2489.
39. Onimaru M., Yonemitsu Y. Angiogenic and lymphangiogenic cascades in the tumor microenvironment. Front. Biosci. (Schol. Ed.) 2011, 3:216-225.
40. Sorensen E.W., Gerber S.A., Frelinger J.G., Lord E.M. IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms. J. Immunol. 2010, 184:1858-1866.
41. Lopez-Lazaro M. HIF-1: hypoxia-inducible factor or dysoxia-inducible factor?. FASEB J. 2006, 20:828-832.
42. Myllyharju J. HIF prolyl 4-hydroxylases and their potential as drug targets. Curr. Pharm. Des. 2009, 15:3878-3885.
43. Langhammer S., Najjar M., Hess-Stumpp H., Thierauch K.H. LDH-A influences hypoxia-inducible factor 1alpha (HIF1 alpha) and is critical for growth of HT29 colon carcinoma cells in vivo. Target. Oncol. 2011, 6:155-162.
44. Parks C.J., Pouyssegur J. pH control mechanisms of tumor survival and growth. J. Cell. Physiol. 2011, 226:299-308.
45. Theodoropoulos G.E., Lazaris A.C., Theodoropoulos V.E., Papatheodosiou K., Gazouli M., Bramis J., Patsouris E., Panoussopoulos D. Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer. Int. J. Colorectal Dis. 2006, 21:248-257.
46. Swinson D.E., Jones J.L., Cox G., Richardson D., Harris A.L., O'Byrne K.J. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int. J. Cancer 2004, 111:43-50.
47. Ma X., Bi H., Qu Y., Xie X., Li J. The contrasting effect of estrogen on mRNA expression of VEGF in bovine retinal vascular endothelial cells under different oxygen conditions. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249:871-877.
48. Recchia A.G., De Francesco E.M., Vivacqua A., Sisci D., Panno M.L., Ando S., Maggiolini M. The G protein-coupled receptor 30 is up-regulated by hypoxia-inducible factor-1alpha (HIF-1alpha) in breast cancer cells and cardiomyocytes. J. Biol. Chem. 2011, 286:10773-10782.
49. Hua K., Din J., Cao Q., Feng W., Zhang Y., Yao L., Huang Y., Zhao Y., Feng Y. Estrogen and progestin regulate HIF-1alpha expression in ovarian cancer cell lines via the activation of Akt signaling transduction pathway. Oncol. Rep. 2009, 21:893-898.
50. Seifert A., Taubert H., Hombach-Klonisch S., Fischer B., Navarrete Santos A. TCDD mediates inhibition of p53 and activation of ERalpha signaling in MCF-7 cells at moderate hypoxic conditions. Int. J. Oncol. 2009, 35:417-424.
51. Kansakar E., Chang Y.J., Mehrabi M., Mittal V. Expression of estrogen receptor, progesterone receptor, and vascular endothelial growth factor-A in thyroid cancer. Am. Surg. 2009, 75:785-789.